BRPI0414082A - formas de dosagem de liberação sustentada de ziprasidona - Google Patents

formas de dosagem de liberação sustentada de ziprasidona

Info

Publication number
BRPI0414082A
BRPI0414082A BRPI0414082-6A BRPI0414082A BRPI0414082A BR PI0414082 A BRPI0414082 A BR PI0414082A BR PI0414082 A BRPI0414082 A BR PI0414082A BR PI0414082 A BRPI0414082 A BR PI0414082A
Authority
BR
Brazil
Prior art keywords
ziprasidone
sustained
dosage forms
release dosage
dosage form
Prior art date
Application number
BRPI0414082-6A
Other languages
English (en)
Inventor
Imran Ahmed
Walter Christian Babcock
Dwayne Thomas Friesen
Scott Max Herbig
Sheri Lynn Shamblin
Ravi Mysore Shanker
Daniel Tod Smithey
Steven C Sutton
Avinash Govind Thombre
Kenneth C Waterman
David Keith Lyon
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0414082A publication Critical patent/BRPI0414082A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMAS DE DOSAGEM DE LIBERAçãO SUSTENTADA DE ZIPRASIDONA". A presente invenção refere-se a uma forma de dosagem oral sólida de liberação sustentada para o tratamento de um distúrbio psicótico, por exemplo a esquizofrenia, em um mamífero, cuja forma de dosagem oral compreende ziprasidona em uma quantidade eficaz para tratar o referido distúrbio psicótico e um veículo farmaceuticamente aceitável.
BRPI0414082-6A 2003-09-02 2004-08-31 formas de dosagem de liberação sustentada de ziprasidona BRPI0414082A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49948403P 2003-09-02 2003-09-02
PCT/US2004/028304 WO2005020929A2 (en) 2003-09-02 2004-08-31 Sustained release dosage forms of ziprasidone

Publications (1)

Publication Number Publication Date
BRPI0414082A true BRPI0414082A (pt) 2006-10-24

Family

ID=34272825

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414082-6A BRPI0414082A (pt) 2003-09-02 2004-08-31 formas de dosagem de liberação sustentada de ziprasidona

Country Status (16)

Country Link
US (2) US20070190129A1 (pt)
EP (1) EP1663166A2 (pt)
JP (1) JP2007504266A (pt)
KR (3) KR20060115350A (pt)
CN (1) CN1874761A (pt)
AR (1) AR046811A1 (pt)
AU (1) AU2004268663B2 (pt)
BR (1) BRPI0414082A (pt)
CA (1) CA2537413A1 (pt)
IL (1) IL173866A0 (pt)
MX (1) MXPA06002455A (pt)
NO (1) NO20061517L (pt)
RU (1) RU2351316C2 (pt)
TW (1) TW200526221A (pt)
WO (1) WO2005020929A2 (pt)
ZA (1) ZA200601602B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
EP1753402B1 (en) 2004-05-28 2008-10-01 Pfizer Products Incorporated Pharmaceutical compositions with enhanced performance comprising a hpmca polymer
MX2007002375A (es) * 2004-08-31 2007-04-23 Pfizer Prod Inc Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad.
JP2008511607A (ja) * 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
GB2465896B (en) * 2007-01-29 2011-12-07 Teraview Ltd A pharmaceutical analysis method and apparatus
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
MX2010009844A (es) * 2008-03-07 2010-09-30 Pfizer Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
DE102008045854A1 (de) * 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
KR101704156B1 (ko) * 2008-11-25 2017-02-07 미쓰비시 타나베 파마 코퍼레이션 구강 내 속붕괴성정을 제조하기 위한 혼합물
RU2421230C2 (ru) * 2009-07-23 2011-06-20 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ предотвращения десульфатирования и повышения биодоступности биологически активных сульфатированных полисахаридов при их пероральном применении
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
JP5787881B2 (ja) * 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
WO2011148253A2 (en) * 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
PL391810A1 (pl) * 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
US20120167410A1 (en) * 2010-12-21 2012-07-05 Basf Se Spray drying techniques
WO2012122279A1 (en) * 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CA2937243C (en) * 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
CN107427468B (zh) * 2014-12-24 2022-02-25 普林斯匹亚生物制药公司 Btk抑制剂的部位特异性给药
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP6855469B2 (ja) * 2015-10-16 2021-04-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 消化器標的療法のための処方物を調製するための工程
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
CA3044867A1 (en) * 2016-11-28 2018-05-31 Gerard P. Mcnally Process for making a coated dosage form
WO2019168985A1 (en) * 2018-02-27 2019-09-06 Delpor, Inc. Compositions for small molecule therapeutic agent compounds
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
EP3968979B1 (en) 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP4247340A4 (en) * 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2261678A (en) * 1937-06-17 1941-11-04 Westinghouse Electric & Mfg Co Electrical flasher system
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TR199802241T2 (pt) * 1996-05-07 1999-02-22 Pfizer Inc.
GB9706714D0 (en) * 1997-04-02 1997-05-21 Reckitt & Colman Inc Improvements in or relating to organic compositions
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7030142B1 (en) * 1999-04-06 2006-04-18 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
DK1242055T3 (da) * 1999-12-23 2008-07-21 Pfizer Prod Inc Hydrogelstyret doseringsform til lægemidler
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
EP1575616A2 (en) * 2002-10-25 2005-09-21 Pfizer Products Inc. Novel injectable depot formulations
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Also Published As

Publication number Publication date
KR20090080143A (ko) 2009-07-23
WO2005020929A2 (en) 2005-03-10
WO2005020929A3 (en) 2005-08-25
ZA200601602B (en) 2007-05-30
KR20080093464A (ko) 2008-10-21
MXPA06002455A (es) 2006-08-31
EP1663166A2 (en) 2006-06-07
US20070190129A1 (en) 2007-08-16
NO20061517L (no) 2006-06-02
CA2537413A1 (en) 2005-03-10
US20100003331A1 (en) 2010-01-07
RU2006106464A (ru) 2007-09-10
CN1874761A (zh) 2006-12-06
RU2351316C2 (ru) 2009-04-10
AU2004268663B2 (en) 2010-12-09
JP2007504266A (ja) 2007-03-01
KR20060115350A (ko) 2006-11-08
IL173866A0 (en) 2006-07-05
AR046811A1 (es) 2005-12-28
TW200526221A (en) 2005-08-16
AU2004268663A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2005020929A3 (en) Sustained release dosage forms of ziprasidone
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
PT1485127E (pt) Administração de agentes para o tratamento de inflamação
CY2014031I1 (el) Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
BR0200155A (pt) Tratamento combinado para depressão
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
TW200716139A (en) Methods and compositions for managing psychotic disorders
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MA31145B1 (fr) Composition antivirale et procede d'utilisation
ITTO20040621A1 (it) Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive
TW200718689A (en) 2-Amino-quinazolin-5-ones
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
HUP0402421A3 (en) Composition inhibiting matrix-metalloproteinases for the treatment of neoplastic diseases
BRPI0415123A (pt) uso de l-butilftalida e respectiva composição farmacêutica
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
DE602006003415D1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
FR2886850B1 (fr) Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
ATE455540T1 (de) Orale dosierform für die kontrollierte arzneimittelfreisetzung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.